Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC
Compare the effect of liver transplantation (LT) plus ADV-TK gene therapy versus LT only in advanced primary hepatocellular carcinoma.
Hepatocellular Carcinoma
DRUG: ADV-Tk|PROCEDURE: LT
Progression-free survival, PFS, PFS was measured from the day of liver transplantation to objective recurrence (MRI or CT) or HCC-related death, whichever occurred first., 2-year
Overall survival, OS, OS was measured from the day of liver transplantation to death., 1-year|Overall survival, OS, OS was measured from the day of liver transplantation to death., 2-year|Time of the tumor progression,TTP, TTP was the median period from the day of liver transplantation to objective recurrence (MRI or CT)., 2-year|Median overall survival time, 2-year
Compare the effect of liver transplantation (LT) plus ADV-TK gene therapy versus LT only in advanced primary hepatocellular carcinoma.